Jump to Main Content


Supported Research

Applicants must submit proposals to conduct research in hematology. Proposals that fall within any of the categories discussed below are encouraged.

Basic Research

ASH considers basic research to include a broad spectrum of studies on genes, proteins, lipids, carbohydrates, biochemical and signaling pathways, receptors, hematopoietic cells, and samples obtained from human patients or from vertebrate animal models. For the purpose of this grant, hematology-related basic research is designed to further our understanding of the blood, bone marrow, and related organs and/or the pathogenesis of blood disorders. The emphasis for grants in this category should be on the discovery of new knowledge in a traditional laboratory setting.

Translational Research

ASH defines translational research as using knowledge of human biology to develop and test the feasibility of relevant interventions in humans and/or to determine the biological basis for observations made in individuals with hematologic conditions or in populations at risk. Translational research should be founded on and directly connected to some aspect of human biology and may encompass any form of structural, biochemical, genetic, or other appropriate experimental approaches using human materials.

Patient-Oriented Clinical Research

Patient-oriented research is defined as research conducted with human subjects and involves an investigator directly interacting with human subjects. Categories of patient-oriented research include mechanisms of human disease, therapeutic interventions, clinical trials, and development of new technologies.

Outcomes-Based Research

Options for outcomes-based research include: a decision-analysis or cost-effectiveness analysis of a relevant topic within hematology; survey-based research investigating practice patterns, access to care, quality of care, clinical outcomes, or quality of life among patients with hematologic conditions; retrospective analyses of large administrative databases (e.g., CMS, a large insurer, SEER) that may enlighten health care policy decisions related to hematologic disease; and large-scale epidemiologic or genetic epidemiologic studies that define the incidence, prevalence, prognosis, and natural history or the effects of therapy of blood disorders.